natgillin/translations-raw huggingface dataset:
p-value is from the pairwise comparison of methotrexate monotherapy and adalimumab/methotrexate combination therapy using the Mann-Whitney U test. p-value is from the pairwise comparison of adalimumab monotherapy and adalimumab/methotrexate combination therapy using the Mann-Whitney U test p-value is from the pairwise comparison of adalimumab monotherapy and methotrexate monotherapy 
Vrednost p se nanaša na parno primerjavo monoterapije z metotreksatom in kombinirane terapije z adalimumabom/metotreksatom z Mann-Whitneyevim testom U Vrednost p se nanaša na parno primerjavo monoterapije z adalimumabom in kombinirane terapije z adalimumabom/metotreksatom z Mann-Whitneyevim testom U Vrednost p se nanaša na parno primerjavo monoterapije z adalimumabom in monoterapije z metotreksatom z Mann
Patients demonstrating a Paediatric ACR 30 response at week 16 were eligible to be randomised into the double blind (DB) phase and received either adalimumab 24 mg/m² up to a maximum of 40 mg, or placebo every other week for an additional 32 weeks or until disease flare. 
Bolniki, ki so 16. teden dosegli odziv "Pediatric ACR" 30, so bili primerni za randomizacijo v dvojno slepo fazo in so nadaljnjih 32 tednov ali do zagona bolezni vsak drugi teden dobili adalimumab 24 mg/m2 (do največ 40 mg) ali placebo.
In CD Study II, 325 patients who had lost response or were intolerant to infliximab were randomised to receive either 160 mg adalimumab at week 0 and 80 mg at week 2 or placebo at weeks 0 and 2. 
V študiji pri Crohnovi bolezni II so 325 bolnikov, ki so se nehali odzivati na infliksimab ali ga niso prenesli, randomizirali bodisi na 160 mg adalimumaba 0. teden in 80 mg 2. teden bodisi na placebo 0. in 2. teden.
If these medicines do not work well enough, you will be given Cyltezo to treat your rheumatoid arthritis. 
Če ta zdravila pri vas ne delujejo dovolj dobro, boste za zdravljenje revmatoidnega artritisa dobili zdravilo Cyltezo.
The safety and efficacy of adalimumab were studied in adult patients with chronic plaque psoriasis (≥ 10 % BSA involvement and Psoriasis Area and Severity Index (PASI) ≥ 12 or ≥ 10) who were candidates for systemic therapy or phototherapy in randomised, double-blind studies. 
Varnost in učinkovitost adalimumaba so v randomiziranih, dvojno slepih študijah raziskali pri odraslih bolnikih s kronično psoriazo v plakih (zajete ≥ 10 % telesne površine ter indeksom obsežnosti in izrazitosti psoriaze (PASI, Psoriasis Area and Severity Index) ≥ 12 ali ≥ 10), ki so bili kandidati za sistemsko zdravljenje ali fototerapijo.
In patients with polyarticular JIA who were 2 to < 4 years old or aged 4 and above weighing < 15 kg dosed with adalimumab 24 mg/m² , the mean trough steady-state serum adalimumab concentrations was 6.0 ± 6.1 μg/mL (101 % CV) for adalimumab without concomitant methotrexate and 7.9 ± 5.6 μg/mL (71.2 % CV) with concomitant methotrexate. 
Pri bolnikih s poliartikularnim JIA, starih od 2 do < 4 leta ali starih 4 leta ali več in s telesno maso < 15 kg, ki so prejemali adalimumab v odmerku 24 mg/m2, je bila povprečna najmanjša koncentracija adalimumaba v serumu v stanju dinamičnega ravnovesja 6,0 ± 6,1 µg/ml (KV 101 %) med uporabo adalimumaba brez metotreksata in 7,9 ± 5,6 µg/ml (KV 71,2 %) med sočasno uporabo metotreksata.
Anti-adalimumab antibodies may develop during adalimumab treatment. 
Med zdravljenjem z adalimumabom lahko nastajajo protitelesa proti adalimumabu.
Efficacy Response in Placebo-Controlled Period for Study nr-axSpA II 
Preglednica 15: Odziv učinkovitosti v s placebom kontroliranem obdobju študije nr-axSpA II Dvojno slepa
Patients were randomised to receive either 24 mg/m² body surface area (BSA) of adalimumab up to a maximum of 40 mg, or placebo every other week for 12 weeks. 
Bolniki so bili randomizirani za prejemanje bodisi 24 mg/m2 telesne površine adalimumaba do največjega posamičnega odmerka 40 mg ali placebo vsak drugi teden, 12 tednov.
Upon completion of both studies, 383 patients enrolled in an open-label extension study, in which 40 mg adalimumab was administered every other week. 
Po koncu obeh študij so 383 bolnikov vključili v odprto nadaljevalno študijo, med katero so bolniki dobivali 40 mg
Cyltezo can slow down the damage to the cartilage and bone of the joints caused by the disease and improve 
Zdravilo Cyltezo lahko upočasni napredovanje prizadetosti sklepnih hrustancev in kosti, ki jo povzroči bolezen, in izboljša
Assessment of SpondyloArthritis international Society Baseline is defined as open label baseline when patients have active disease. 
Delni zagon bolezni ocena spondiloartritičnega mednarodnega združenja (Assessment of Spondyloarthritis international Society) izhodišče je določeno kot izhodišče odprte faze, ko imajo bolniki aktivno bolezen ocena bolezenske aktivnosti ankilozirajočega spondilitisa (Ankylosing Spondylitis Disease
The double-blind period was followed by an open-label period during which patients receive adalimumab 40 mg every other week subcutaneously for up to an additional 144 weeks. 
Dvojno slepi periodi je sledila odprta perioda, v kateri so bolniki prejemali adalimumab 40 mg vsak drug teden subkutano do dodatnih 144 tednov.
In RA study IV, the ACR 20 response of patients treated with adalimumab plus standard of care was statistically significantly better than patients treated with placebo plus standard of care (p < 0.001). 
V študiji revmatoidnega artritisa IV je bil odziv 20 po ACR pri bolnikih, zdravljenih z adalimumabom in standardno oskrbo, statistično značilno boljši kot pri bolnikih, zdravljenih s placebom in standardno
Fatal and life-threatening infections (including sepsis, opportunistic infections and TB), HBV reactivation and various malignancies (including leukaemia, lymphoma and HSTCL) have also been reported with use of 
V povezavi z jemanjem adalimumaba so poročali tudi o smrtnih in življenjsko ogrožajočih okužbah (vključno s sepso, oportunističnimi okužbami in TB), HBV reaktivaciji in različnih malignih obolenjih (vključno z levkemijo, limfomom in HSTCL).
Carriers of HBV who require treatment with Cyltezo should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy. 
Nosilce HBV, ki potrebujejo zdravljenje z zdravilom Cyltezo, je treba ves čas zdravljenja in več mesecev po koncu zdravljenja natančno spremljati glede znakov in simptomov aktivne okužbe s HBV. O zdravljenju nosilcev HBV s protivirusno terapijo v kombinaciji z antagonistom TNF za preprečitev reaktivacije HBV ni zadostnih podatkov.
The inner part of the cap of the syringe (the needle cover) contains natural rubber (latex). 
Notranji del pokrovčka injekcijske brizge (pokrovček igle) vsebuje naravni kavčuk (lateks).
Cyltezo dose for paediatric patients with Crohn's disease 
Preglednica 4: Odmerjanje zdravila Cyltezo pri pediatričnih bolnikih s Crohnovo boleznijo
Following subcutaneous administration of 40 mg of adalimumab every other week in adult rheumatoid arthritis (RA) patients the mean steady-state trough concentrations were approximately 5 μg/mL (without concomitant methotrexate) and 8 to 9 μg/mL (with concomitant methotrexate), respectively. 
Po subkutani uporabi 40 mg adalimumab vsak drugi teden pri odraslih bolnikih z revmatoidnim artritisom (RA) so bile povprečne najmanjše koncentracije v stanju dinamičnega ravnovesja približno 5 μg/ml (brez sočasne uporabe metotreksata) in od 8 do 9 μg/ml (s sočasno uporabo metotreksata).
Visual impairment, conjunctivitis, blepharitis, eye swelling 
motnje vidnega zaznavanja, konjunktivitis, blefaritis, otekanje oči občasni diplopija
• Discard entire Cyltezo pen into “sharps” container. 
• Celoten peresnik z zdravilom Cyltezo vrzite v vsebnik za ostre predmete.
In controlled Phase 3 trials of adalimumab in patients with polyarticular juvenile idiopathic arthritis who were 4 to 17 years and enthesitis-related arthritis who were 6 to 17 years, ALT elevations ≥ 3 x ULN occurred in 6.1 % of adalimumab-treated patients and 1.3 % of control-treated patients. 
V kontroliranih preskušanjih faze 3 z adalimumabom pri bolnikih z juvenilnim idiopatskim artritisom, ki so bili stari od 4 do 17 let in bolnikih z artritisom, povezanim z entezitisom, ki so bili stari od 6 do 17 let, so se zvišanja ALT ≥ 3 x ULN pojavila pri 6,1 % bolnikov zdravljenih z adalimumabom, in pri 1,3 % bolnikov v kontrolni skupini.
The mean steady-state trough concentration at week 12 through week 36 were approximately 8 to 10 µg/mL during adalimumab 40 mg every week treatment. 
Najnižja koncentracija pred naslednjim odmerkom v stanju dinamičnega ravnovesja je bila približno 8 do 10 µg/ml med 12. tednom in 36. tednom pri zdravljenju z odmerkom 40 mg adalimumaba vsak teden.
If these medicines do not work well enough, you will be given Cyltezo to reduce the signs and symptoms of your disease. 
Če ta zdravila ne bodo delovala dovolj dobro, boste dobili zdravilo Cyltezo za zmanjšanje znakov in simptomov vaše bolezni.
In Study nr-axSpA I, adalimumab 40 mg every other week was assessed in 185 patients in a randomised, 12 week double-blind, placebo-controlled study in patients with active nr-axSpA (mean baseline score of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.4 for patients treated with adalimumab and 6.5 for those on placebo) who have had an inadequate response to or intolerance to ≥ 1 NSAIDs, or a contraindication for NSAIDs. 
Uporabo adalimumaba 40 mg vsak drugi teden so proučili v randomizirani, 12 tednov trajajoči, dvojno slepi, s placebom kontrolirani študiji nr-axSpA I pri 185 bolnikih z aktivnim nr-axSpA (srednja vrednost aktivnosti bolezni po BASDAI] je bila 6,4 pri bolnikih zdravljenih z adalimumabom in 6,5 pri bolnikih na placebu), ki so nezadostno reagirali na ali niso prenašali vsaj enega NSAID ali s
The recommended dose of Cyltezo for adult patients with rheumatoid arthritis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection. 
Priporočeni odmerek zdravila Cyltezo za odrasle bolnike z revmatoidnim artritisom je 40 mg adalimumaba vsak drugi teden v enkratnem odmerku v subkutani injekciji.
***, **, * Statistically significant at p < 0.001, < 0.01, and < 0.05, respectively, for all comparisons between 
***, **, * Statistično pomembno pri p < 0,001, < 0,01 in < 0,05, v tem zaporedju, za vse primerjave med adalimumabom in
• Do not give Cyltezo to children with polyarticular juvenile idiopathic arthritis below the age of 2 years. 
• Zdravila Cyltezo ne smete dati otrokom s poliartikularnim juvenilnim idiopatskim artritisom, če
Adults with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or axial spondyloarthritis without radiographic evidence of ankylosing spondylitis The usual dose for adults with rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of ankylosing spondylitis and for patients with psoriatic arthritis is 40 mg adalimumab given every other week as a single dose. 
Običajni odmerek za odrasle z revmatoidnim artritisom, ankilozirajočim spondilitisom, aksialnim spondiloartritisom brez radiografskega dokaza za ankilozirajoči spondilitis in za bolnike s psoriatičnim artritisom je 40 mg adalimumaba vsak drugi teden v enkratnem odmerku.
The needle cover of the syringe contains natural rubber (latex). 
Pokrovček za iglo na injekcijski brizgi vsebuje naravni kavčuk (lateks).
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Cyltezo 40 mg injection 
IME ZDRAVILA IN POT(I) UPORABE Cyltezo 40 mg injekcija adalimumab subkutana uporaba
• There have been cases of cancers other than lymphoma in patients with a specific type of lung disease called chronic obstructive pulmonary disease (COPD) treated with another TNFα blocker. 
• Pri bolnikih s posebno boleznijo pljuč, t.i. kronično obstruktivno pljučno boleznijo (KOPB), zdravljenih z nekim drugim zaviralcem TNFα, so bili primeri rakov, ki niso bili limfomi.
It is recommended that the patient should use a topical antiseptic wash on their HS lesions on a daily basis during treatment with Cyltezo. 
Priporočljivo je, da med zdravljenjem z zdravilom Cyltezo bolnik vsak dan uporablja topikalno antiseptično čistilno sredstvo za čiščenje lezij HS.
Radiographic Mean Changes at Week 52 in RA Study V MTX n=257 confidence interval) 
Povprečne rentgenografske spremembe po 52 tednih študije adalimumab/ MTX n = 268 (95-% interval zaupanja)
ACR Responses in RA Study V (percent of patients) 
Preglednica 8: Odzivi ACR v študiji revmatoidnega artritisa V (odstotek bolnikov)
Patients received adalimumab 0.8 mg/kg eow (up to 40 mg), 0.4 mg/kg eow (up to 20 mg), or methotrexate 0.1-0.4 mg/kg weekly (up to 25 mg). 
Bolniki so prejemali adalimumab v odmerkih 0,8 mg/kg vsak drugi teden (do največ 40 mg), 0,4 mg/kg vsak drugi teden (do največ 20 mg) ali 0,1 - 0,4 mg/kg metotreksata na teden (do največ
Cyltezo dose for patients with enthesitis-related arthritis 
Preglednica 2: Odmerjanje zdravila Cyltezo pri bolnikih z artritisom, povezanim z entezitisom
Of these skin cancers, squamous cell carcinomas occurred at rates (95 % confidence interval) of 2.7 (1.4, 5.4) per 1,000 patient-years among adalimumab-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-years among control patients. 
Med temi kožnimi raki je bil delež (95-% interval zaupanja) ploščatoceličnega karcinoma 2,7 (1,4; 5,4) na 1.000 bolnikov-let med bolniki, ki so dobivali adalimumab, in 0,6 (0,1; 4,5) na 1.000 bolnikov-let v kontrolni skupini bolnikov.
The recommended dose of Cyltezo for patients with Crohn's disease from 6 to 17 years of age is based on body weight (Table 4). 
Priporočeni odmerek zdravila Cyltezo pri bolnikih s Crohnovo boleznijo, starih od 6 do 17 let, temelji na telesni masi (preglednica 4).
Children and adolescents from 4 to 17 years of age weighing 30 kg or more The recommended dose of Cyltezo is an initial dose of 40 mg, followed by 40 mg one week later. 
Otroci in mladostniki, stari od 4 do 17 let, ki tehtajo 30 kg ali več Priporočeni odmerek zdravila Cyltezo je začetni odmerek 40 mg, ki mu sledi 40 mg en teden kasneje.
Keep this 
Pritisnite in držite
Cyltezo is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom 
Zdravilo Cyltezo je indicirano za zdravljenje kroničnega, neinfekcijskega, anteriornega uveitisa pri pediatričnih bolnikih, starejših od 2 let, ki se niso ustrezno odzvali ali ne prenašajo konvencionalnega zdravljenja, ali pri katerih konvencionalno zdravljenje ni primerno.
• Gently remove cap by pulling it straight off. Do not touch needle or let needle touch anything. 
Ne dotikajte se igle, prav tako se z iglo ničesar ne dotikajte.
Available data suggest that clinical response is usually achieved within 12 weeks of treatment. 
Razpoložljivi podatki kažejo, da je klinični odziv ponavadi dosežen v 12 tednih zdravljenja.
In the OL LI phase all patients received 24 mg/m² up to a maximum of 40 mg adalimumab every other week for 16 weeks. 
V odprti uvajalni fazi so vsi bolniki 16 tednov dobivali 24 mg/m2 (do največ 40 mg) adalimumaba vsak drugi teden.
*** p < 0.001 for all comparisons between adalimumab and placebo * p < 0.05 for all comparisons between adalimumab and placebo 
*** p < 0,001 za vse primerjave med adalimumabom in placebom * p < 0,05 za vse primerjave med adalimumabom in placebom
Adalimumab has not been studied in patients aged less than 2 years. 
Raziskave z adalimumabom pri bolnikih, mlajših od 2 let, niso bile izvedene.
Cyltezo is used to treat rheumatoid arthritis in adults. 
Zdravilo Cyltezo se uporablja za zdravljenje revmatoidnega artritisa pri odraslih.
Concurrent administration of biologic DMARDS or TNF-antagonists Serious infections were seen in clinical studies with concurrent use of anakinra and another TNF-antagonist, etanercept, with no added clinical benefit compared to etanercept alone. 
V kliničnih študijah s sočasno uporabo anakinre in etanercepta, drugega antagonista TNF, so opazili hude okužbe brez dodatnih kliničnih prednosti v primerjavi z etanerceptom samim.
(See section 4.5). 
(glejte podatke za odrasle bolnike v poglavju 5.1).
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PEN LABEL 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
It is recommended that the conduct and results of these tests are recorded in the patient alert card. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised. 
Zdravniki se morajo zavedati tveganja za lažno negativne izvide tuberkulinskega kožnega testa, zlasti pri hudo bolnih ali imunsko oslabelih bolnikih.
• allergic reactions (including seasonal allergy); 
• alergijske reakcije (vključno s sezonskimi alergijami); • spremenljivo razpoloženje (vključno z depresijo);
Patients should be instructed to seek medical advice if signs/symptoms suggestive of a tuberculosis infection (e.g., persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after therapy with 
Bolnikom je treba naročiti, naj poiščejo zdravniško pomoč, če med zdravljenjem z zdravilom Cyltezo ali po njem doživijo znake ali simptome, ki nakazujejo tuberkulozno okužbo (npr. trdovraten kašelj, hujšanje/izgubljanje teže, nekoliko zvišano telesno temperaturo).
• Do not reuse a used pre-filled syringe. 
• Napolnjene injekcijske brizge ne uporabite znova.
If symptoms of tuberculosis (persistent cough, weight loss, listlessness, mild fever), or any other infection appear during or after therapy tell your 
Če se med zdravljenjem ali po njem pojavijo simptomi tuberkuloze (trdovraten kašelj, hujšanje, brezvoljnost, rahlo zvišana telesna temperatura) ali kakšne druge okužbe, o tem takoj obvestite zdravnika.
In adult Crohn's disease studies, higher incidences of malignant and serious infection-related adverse events were seen with the combination of adalimumab and azathioprine/6-mercaptopurine compared with 
V študijah Crohnove bolezni pri odraslih so pri sočasni uporabi adalimumaba in azatioprina/6-merkaptopurina opazili večjo incidenco malignih in resnih z okužbo povezanih neželenih dogodkov kot pri zdravljenju samo z adalimumabom.
Serious allergic reactions associated with adalimumab were rare during clinical trials. 
V kliničnih preskušanjih so bile redke resne alergijske reakcije, povezane z adalimumabom.
o Expiration date on pen or carton has passed o Medication is cloudy, discoloured, frozen, or contains flakes or particles o Pen appears cracked, damaged, or leaking 
• Peresnika zdravila Cyltezo NE uporabite, če: ○ je datum roka uporabnosti peresnika ali škatle potekel; ○ je zdravilo motno, obarvano, zamrznjeno ali vsebuje kosmiče ali delce; ○ je peresnik videti počen, poškodovan ali pušča;
The safety profile for patients with uveitis treated with adalimumab every other week was consistent with the 
Varnostni profil za bolnike z uveitisom, ki so bili vsak drugi teden zdravljeni z adalimumabom, je v skladu z znanim varnostnim profilom adalimumaba.
Systemic infections (including sepsis, candidiasis and influenza), intestinal infections (including gastroenteritis viral), skin and soft tissue infections (including paronychia, cellulitis, impetigo, necrotising fasciitis and herpes zoster), ear infections, oral infections (including herpes simplex, oral herpes and tooth infections), reproductive tract infections (including vulvovaginal mycotic infection), urinary tract infections (including pyelonephritis), fungal infections, joint infections 
pogosti sistemske okužbe (vključno s sepso, kandidiazo in gripo), črevesne okužbe (vključno z virusnim gastroenteritisom), okužbe kože in mehkih tkiv (vključno z paronihijo, celulitisom, impetigom, nekrotizirajočim fasciitisom in herpesom zostrom), okužbe ušes, okužbe ustne votline (vključno s herpesom simpleksom, ustnim herpesom in okužbami zob), okužbe rodil (vključno z vulvovaginalno mikotično okužbo), okužbe sečil (vključno s pielonefritisom), glivične okužbe, okužbe sklepov nevrološke okužbe (vključno z virusnim meningitisom), oportunistične okužbe in tuberkuloza (vključno s kokidioidomikozo, histoplazmozo in kompleksno okužbo z Mycobacterium avium), bakterijske okužbe, okužbe oči, divertikulitis karcinom kože, razen melanoma (vključno z bazalnoceličnim karcinomom in ploščatoceličnim karcinomom), benigni tumor limfom**, novotvorbe na parenhimskih organih (vključno z rakom dojk, novotvorbo na pljučih in novotvorbo na ščitnici), melanom**
In CD Study I, 299 TNF-antagonist naive patients were randomised to one of four treatment groups; placebo at weeks 0 and 2, 160 mg adalimumab at week 0 and 80 mg at week 2, 80 mg at week 0 and 40 mg at week 2, and 40 mg at week 0 and 20 mg at week 2. 
V študiji pri Crohnovi bolezni I so 299 bolnikov, ki pred tem še niso dobivali antagonistov TNF, randomizirali v eno od štirih skupin: placebo 0. in 2. teden, 160 mg adalimumaba 0. teden in 80 mg 2. teden, 80 mg 0. teden in 40 mg 2. teden oziroma 40 mg 0. teden in 20 mg 2. teden.
Adalimumab was assessed in a multicentre, randomised, double-blind clinical trial designed to evaluate the efficacy and safety of induction and maintenance treatment with doses dependent on body weight (< 40 kg or ≥ 40 kg) in 192 paediatric subjects between the ages of 6 and 17 (inclusive) years, with moderate to severe Crohn´s disease (CD) defined as Paediatric Crohn's Disease Activity Index (PCDAI) score > 30. 
Adalimumab je bil ocenjen v multicentrični, randomizirani, dvojno slepi klinični študiji, ki je bila zasnovana za oceno učinkovitosti in varnosti uvodnega in vzdrževalnega zdravljenja z odmerki, odvisnimi od telesne mase (< 40 mg ali ≥ 40 mg) pri 192 pediatričnih bolnikih med 6. in 17.
Adolescent hidradenitis suppurativa (from 12 years of age, weighing at least 30 kg) There are no clinical trials with adalimumab in adolescent patients with HS. 
Hidradenitis suppurativa pri mladostnikih (starejših od 12 let, ki tehtajo najmanj 30 kg) Kliničnih preskušanjih z adalimumabom pri mladostnikih s HS ni. Odmerjanje adalimumaba pri teh bolnikih je bilo določeno na podlagi farmakokinetičnega modeliranja in simulacije (glejte
Following the administration of 24 mg/m² (up to a maximum of 40 mg) subcutaneously every other week to patients with enthesitis-related arthritis who were 6 to 17 years, the mean trough steady-state (values measured at week 24) serum adalimumab concentrations were 8.8 ± 6.6 μg/mL for adalimumab without concomitant methotrexate and 11.8 ± 4.3 μg/mL with concomitant methotrexate. 
2 (do največ 40 mg) subkutano vsak drugi teden bolnikom z artritisom, povezanim z entezitisom, ki so bili stari od 6 do 17 let, je bila povprečna najmanjša koncentracija adalimumaba v serumu v stanju dinamičnega ravnovesja (vrednost merjena v 24. tednu) 8,8 ± 6,6 μg/ml med uporabo adalimumaba brez metotreksata in 11,8 ± 4,3 μg/ml med sočasno uporabo metotreksata.
• Adults with non-infectious uveitis with inflammation affecting the back of the eye • Children from 2 years of age with chronic non-infectious uveitis with inflammation affecting the 
• otrok, starejših od 2 let, s kroničnim neinfekcijskim uveitisom, kjer vnetje prizadene sprednji del očesa.
Cyltezo is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. 
Zdravilo Cyltezo je indicirano za zdravljenje zmerno do hudo aktivnega ulceroznega kolitisa pri odraslih bolnikih, ki so se ne odzovejo zadostno na običajno zdravljenje, na primer na kortikosteroide in 6-merkaptopurin (6-MP) ali azatioprin (AZA), ali pa takšnega zdravljenja ne prenesejo oz. imajo